Note 4 — Restructuring (credits) charges

The following tables provide information regarding restructuring (credits) charges recognized by the Company for the three and nine months ended October 1, 2017 and September 25, 2016:



Three Months Ended October 1, 2017
	Termination Benefits			Facility Closure Costs		Contract Termination Costs		Other Exit Costs		Total
	(Dollars in thousands)
2017 Vascular Solutions integration program	$	(319	)	$	—	$	—	$	58	$	(261	)
2017 EMEA restructuring program	(714		)	—		—		84		(630		)
2016 Footprint realignment plan	274			72		—		85		431
2014 Footprint realignment plan	197			46		—		6		249
Other restructuring programs ⁽¹⁾	8			—		104		7		119
Total restructuring (credits) charges	$	(554	)	$	118	$	104	$	240	$	(92	)



Three Months Ended September 25, 2016
	Termination Benefits			Facility Closure Costs		Contract Termination Costs		Other Exit Costs		Total
	(Dollars in thousands)
2016 Other Restructuring programs	$	1,713		$	—	$	—	$	—	$	1,713
2016 Footprint realignment plan	851			—		—		74		925
2014 Footprint realignment plan	308			—		—		6		314
Other restructuring programs ⁽²⁾	(88		)	54		107		2		75
Total restructuring charges	$	2,784		$	54	$	107	$	82	$	3,027



Nine Months Ended October 1, 2017
	Termination Benefits		Facility Closure Costs		Contract Termination Costs			Other Exit Costs		Total
	(Dollars in thousands)
2017 Vascular Solutions integration program	$	4,534	$	—	$	—		$	92	$	4,626
2017 EMEA restructuring program	5,822		—		—			84		5,906
2016 Footprint realignment plan	1,099		94		(75		)	214		1,332
2014 Footprint realignment plan	379		60		—			7		446
Other restructuring programs ⁽³⁾	973		58		313			69		1,413
Total restructuring charges	$	12,807	$	212	$	238		$	466	$	13,723



Nine Months Ended September 25, 2016
	Termination Benefits			Facility Closure Costs		Contract Termination Costs		Other Exit Costs		Total
	(Dollars in thousands)
2016 Other Restructuring programs	$	1,713		$	—	$	—	$	—	$	1,713
2016 Footprint realignment plan	10,919			—		—		360		11,279
2014 Footprint realignment plan	(118		)	—		—		17		(101		)
Other restructuring programs ⁽⁴⁾	(487		)	$	232	$	114	126		(15		)
Total restructuring charges	$	12,027		$	232	$	114	$	503	$	12,876


(1)	Other restructuring programs include the 2017 Pyng Integration program and the 2016 Other Restructuring programs. The Company committed to the 2017 Pyng Integration program, which relates to the integration of Pyng into Teleflex, during the second quarter 2017.

(2) Other restructuring programs include the 2015 Restructuring programs and the 2014 European Restructuring Plan.

(3) Other restructuring programs include the 2017 Pyng Integration program, the 2016 Other Restructuring programs, the 2015 Restructuring programs and the 2014 European Restructuring plan.

(4) Other restructuring programs include the 2014 European Restructuring Plan and the 2012 Restructuring program.

2017 Vascular Solutions Integration Program

During the first quarter 2017, the Company committed to a restructuring program related to the integration of Vascular Solutions into Teleflex. The program commenced in the first quarter 2017 and is expected to be substantially completed by the end of the second quarter 2018. The Company estimates that it will record aggregate pre-tax restructuring charges of $6.0 million to $7.5 million related to this program, of which $4.5 million to $5.3 million will constitute termination benefits, while $1.5 million to $2.2 million will relate to other exit costs, including employee relocation and outplacement costs. Additionally, the Company expects to incur $2.5 million to $3.0 million of restructuring related charges consisting primarily of retention bonuses offered to certain employees expected to remain with the Company after completion of the program. All of these charges will result in future cash outlays. As of October 1, 2017, the Company has a restructuring reserve of $1.7 million related to this program.

2017 EMEA Restructuring Program

During the first quarter 2017, the Company committed to a restructuring program to centralize certain administrative functions in Europe. The program commenced in the second quarter 2017 and is expected to be substantially completed by the end of 2018. The Company estimates that it will record aggregate pre-tax restructuring charges of $7.1 million to $8.5 million related to this program, almost all of which constitute termination benefits, and all of which will result in future cash outlays. As of October 1, 2017, the Company has a restructuring reserve of $6.0 million related to this program.

2016 Other Restructuring Programs

During 2016, the Company committed to programs designed to improve operating efficiencies and reduce costs. The programs involve the consolidation of certain global administrative functions and manufacturing operations. The programs commenced in the second half of 2016 and are expected to be substantially complete by the end of the first quarter 2018. The Company estimates that it will record aggregate pre-tax charges of $3.8 million to $4.7 million related to these programs, substantially all of which constitute termination benefits that will result in future cash outlays. Additionally, the Company expects to incur approximately $1.5 million of accelerated depreciation and other costs directly related to these programs, which the Company anticipates will be recognized in cost of goods sold. Approximately $1.0 million of these costs are expected to result in future outlays. As of October 1, 2017, the Company has a restructuring reserve of $0.8 million related to these programs.

2016 Footprint Realignment Plan

In 2016, the Company initiated a restructuring plan (the “2016 footprint realignment plan") designed to reduce costs, improve operating efficiencies and enhance the Company’s long term competitive position. The plan involves the relocation of certain manufacturing operations, the relocation and outsourcing of certain distribution operations and a related workforce reduction at certain of the Company's facilities. These actions commenced in the first quarter of 2016 and are expected to be substantially completed by the end of 2018. The Company estimates that it will incur aggregate pre-tax restructuring and restructuring related charges in connection with the 2016 footprint realignment plan of between approximately $34 million to $44 million, of which an estimated $27 million to $31 million are expected to result in future cash outlays. Most of these charges, and the related cash outlays, are expected to be made prior to the end of 2018.

In addition to the restructuring charges shown in the tables above, the Company recorded charges related to the 2016 footprint realignment plan of $1.4 million and $5.5 million for the three and nine months ended October 1, 2017, respectively, and $1.9 million and $4.2 million for the three and nine months ended September 25, 2016, respectively. The majority of these restructuring related charges in both periods constituted accelerated depreciation and other costs arising principally as a result of the transfer of manufacturing operations to new locations.

As of October 1, 2017, the Company has incurred restructuring charges in connection with the 2016 footprint realignment plan aggregating to $13.8 million. Additionally, as of October 1, 2017, the Company has incurred restructuring related charges aggregating to $12.0 million related to the 2016 footprint realignment plan, consisting of accelerated depreciation and certain other costs that principally resulted from the transfer of manufacturing operations to new locations. These costs primarily were included in cost of goods sold. As of October 1, 2017, the Company has a restructuring reserve of $7.9 million related to this plan, the majority of which relates to termination benefits.

2014 Footprint Realignment Plan

In 2014, the Company initiated a restructuring plan (“the 2014 footprint realignment plan”) involving the consolidation of operations and a related reduction in workforce at certain facilities, and the relocation of manufacturing operations from certain higher-cost locations to existing lower-cost locations. These actions commenced in the second quarter 2014 and are expected to be substantially completed by the end of the first half of 2020. The Company estimates that it will incur aggregate pre-tax restructuring and restructuring related charges in connection with the 2014 footprint realignment plan of approximately $43 million to $48 million, of which an estimated $33 million to $38 million are expected to result in future cash outlays. The Company expects to incur $24 million to $30 million in aggregate capital expenditures under the plan.

In addition to the restructuring charges set forth in the tables above, the Company recorded charges related to the 2014 footprint realignment plan of $1.0 million and $3.1 million for the three and nine months ended October 1, 2017, respectively, and $2.5 million and $6.9 million for the three and nine months ended September 25, 2016, respectively. The majority of these restructuring related charges in both periods constituted accelerated depreciation and other costs arising principally as a result of the transfer of manufacturing operations to new locations.

As of October 1, 2017, the Company has incurred restructuring charges in connection with the 2014 footprint realignment plan aggregating to $11.5 million. Additionally, as of October 1, 2017, the Company has incurred restructuring related charges aggregating to $25.9 million related to the 2014 footprint realignment plan, consisting of accelerated depreciation and certain other costs that principally resulted from the transfer of manufacturing operations from the existing locations to new locations. These restructuring related charges primarily were included in cost of goods sold. As of October 1, 2017, the Company has a restructuring reserve of $4.2 million in connection with the plan, all of which relates to termination benefits.

For additional information regarding the Company's restructuring programs, see Note 4 to the Company's consolidated financial statements included in its annual report on Form 10-K for the year ended December 31, 2016.

Restructuring (credits) charges by reportable operating segment, and by all other operating segments in the aggregate, for the three and nine months ended October 1, 2017 and September 25, 2016 are set forth in the following table:



	Three Months Ended					Nine Months Ended
	October 1, 2017			September 25, 2016		October 1, 2017		September 25, 2016
	(Dollars in thousands)					(Dollars in thousands)
Restructuring (credits) charges
Vascular North America	$	606		$	960	$	1,715	$	5,474
Anesthesia North America	220			946		1,031		3,185
Surgical North America	—			277		—		257
EMEA	(632		)	89		6,503		3,012
OEM	—			187		—		191
All other	(286		)	568		4,474		757
Total restructuring (credits) charges	$	(92	)	$	3,027	$	13,723	$	12,876